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Objective: Chest tubes are used to clear blood from around the heart and lungs
after heart surgery, but they can be obstructed by a blood clot, leading to retained
blood syndrome (RBS). We sought to examine the frequency of RBS and
associated morbidity, and to determine the influence of a preventative active chest
tube clearance (ATC) protocol on these outcomes.
Methods: A multidisciplinary team developed a simple protocol to institute ATC
to preventatively clear chest tubes of clot during the first 24 hours after heart
surgery. An extensive educational in-service was performed before universal
implementation (phase 1). We retrospectively compared data collected
prospectively from 1849 patients before universal implementation (phase 0)
with data from 256 patients collected prospectively after universal implementa-
tion (phase 2), and then used propensity matching for outcomes assessment.
Results: In propensity-matched patients, 19.9% of patients had interventions for
RBS (phase 0). After the implementation of ATC (phase 2), the percent of patients
with interventions for RBS was reduced to 11.3%, representing a 43% reduction
in RBS (P¼ .0087). These patients had a 33% reduced incidence of postoperative
atrial fibrillation from 30% (78 out of 256) in phase 0 to 20% (52 out of 256) in
phase 2. (P ¼ .013).
Conclusions: ATC is associated with a reduced need for interventions for RBS
and postoperative atrial fibrillation. Our findings underscore the importance of
maintaining chest tube patency in the early hours after cardiac surgery. (J Thorac
Cardiovasc Surg 2016;151:832-38)From the aDepartment of Cardiac Surgery, Kllinikum N€urnberg, Paracelsus Medical
University, Nuremberg, Germany; and bSt Charles Medical Center, Bend, Ore.
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drome and postoperative atrial fibrillation.Central Message
Active tube clearance reduces interventions for
retained blood syndrome and postoperative
atrial fibrillation, underscoring the importance
of maintaining chest tube patency after cardiac
surgery.Perspective
All patients require chest tubes to drain shed
blood after heart surgery, yet clogging of chest
tubes is common. We studied a protocol to
maintain chest tube patency with active tube
clearance and demonstrated an associated
reduction in retained blood syndrome and post-
operative atrial fibrillation. Our findings under-
score the importance of maintaining chest tube
patency in outcomes after cardiac surgery.See Editorial Commentary page 839.Supplemental material is available online.
Postoperative bleeding is common to some degree in nearly
all patients in the early hours after heart surgery.1 To obtainadequate evacuation, chest tubes are used to drain shed
blood and prevent retained collections around the heart
and lungs.2 Chest tubes can obstruct with clot, impairing
their evacuation capacity. Recently, a prospective observa-
tional study3 quantified that 36% of chest tubes obstruct
after heart surgery, often in the internal portion where the
obstruction goes unnoticed by caregivers. We hypothesized
that chest tube obstruction might contribute to retained
blood syndrome (RBS) after cardiac surgery. To study this
hypothesis we initiated a continuous quality improvement
process to assess the incidence of RBS, then develop and
implement a universal protocol using active tube clearance
(ATC) to periodically clear the internal lumen of chest
tubes.MATERIALS AND METHODS
Data were collected from our institutional cardiac surgery database.
Structured data elements are routinely prospectively collected and
Abbreviations and Acronyms
ATC ¼ active tube clearance
CABG ¼ coronary artery bypass surgery
ICU ¼ intensive care unit
NYHA ¼ New York Heart Association
POAF ¼ postoperative atrial fibrillation
RBS ¼ retained blood syndrome
VEGF ¼ vascular endothelial growth factor
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Mavailable for retrospective analysis. Operative variables included the type
of surgery (coronary artery bypass grafting [CABG], valve,
CABG þ valve, and other) and reoperative status. Procedures in the
‘‘other’’ category included isolated ascending and aortic arch procedures.
The primary outcomes measured were interventions for RBS, a composite
outcome consisting of any of the following interventions: take back for
re-exploration for hemorrhage; pericardial interventions (eg, pericardial
window or pericardiocentesis); and pleural interventions for hemothorax,
pneumothorax, or effusions. Patients who had interventions for >1
component of RBSwere only counted once. Patients who had the diagnosis
of pleural or pericardial effusion or hemothorax or hemopneumothorax but
did not undergo a specific invasive intervention were excluded. Secondary
outcomes included postoperative atrial fibrillation (POAF), cardiac arrest,
permanent stroke, postoperative hospital length of stay, and the total chest
tube drainage volume (in milliliters). All patients were fitted with at least 1
28F chest tube in the anterior mediastinum. We do not routinely open the
pleura to harvest the mammary artery, but when it happens, the surgeons
place a pleural 28F chest tube. Rarely, a retro cardiac 28F chest tube is
placed. Blake or channel-type drains were not used in any patient in this
study. All patients were treated with tranexamic acid. An institutional
trigger to transfuse for hemoglobin values of 7.5 to 8 g/dL was adhered
to in all phases of this study.
From January 1, 2011, to June 11, 2014, 3226 adult cardiac surgical
procedures were performed at the Nuremberg Cardiovascular Center.
Patients were divided into 4 phases for analysis.
Phase 0: Pre-ATC Protocol
From January 1, 2011, to December 31, 2012, 1849 cardiac surgery
procedures were performed. No patients in this group were treated
with ATC. These patients were divided into those with any of the RBS
interventions versus those without to establish a baseline for measurement
of clinical outcomes.
Phase 1: Limited Implementation for ATC Protocol
Development, Training, and Compliance Verification
A multidisciplinary team developed a simple protocol to institute ATC
to clear chest tubes during the first 24 hours after heart surgery. The Pleura-
Flow Active Clearance Technology System (ClearFlow, Inc, Anaheim,
Calif) is a chest tube clearance apparatus with a mechanism to actively
keep the entire inner diameter of the chest tube clear of obstructing blood
clot or fibrinous debris.4 Care providers periodically advance a clearance
apparatus back and forth within the catheter by actuating the shuttle that
couples via a magnet to the clearance member to maintain sterility while
the tube is cleared.
Multidisciplinary team meetings were held for protocol development
with cardiac surgical staff, resident physicians and fellows, anesthesiolo-
gists and critical care physicians, and cardiac intensive care unit (ICU)
nurses. The objective was to develop a simple protocol to implement
ATC that could be integrated into the workflow. In prior studies, the
most common sites for bleeding identified at reoperation were the medias-
tinum, sternum, internal thoracic artery bed, and coronary anastomosisThe Journal of Thoracic and Casites.5,6 For sake of simplicity, it was decided to use a single ATC unit
(28F) in an anterior mediastinal position. After 24 hours, the chest tube
with ATC was removed, or the chest tube was left in place and the ATC
pulled back and its use was discontinued. Most were removed by
the second postoperative day. Surgeons were allowed to place
additional conventional chest tubes at their discretion; however, in a
majority only a single mediastinal ATC was used. The protocol
developed allows for more frequent use early on, when chest tube
outputs tend to be higher, and less so in subsequent hours, as well as on
an as-needed basis (Appendix E1).7 The nurses were free to strip and
milk the conventional chest tubes as needed. An extensive
educational in-service was performed before universal implementation
for training of all nurses and physician in the ICU with compliance
verification. This protocol was rolled out in phase 1 starting January 1,
2013, through November 30, 2013, during which time there were 914 heart
surgery cases.
Phase 2: Universal Implementation of ATC Protocol
We implemented phase 2 with ATC universally in all consecutive
patients from December 1, 2013, to March 16, 2014.
Phase 3: Postprotocol Remeasurement
In this phase we stopped the universal implementation of ATC and
returned to using all conventional chest tubes (without ATC) and repeated
measurement of outcomes (March 18-June 11, 2014).
This study was an investigator-initiated study that was supported in part
by a research grant from ClearFlow, Inc. The study site investigators had
full access to the data, the ability to analyze them independently from
the sponsor, and sole authority to make the final decision regarding
publication. ClearFlow, Inc, played no role in the collection of data
and had no right to approve or disapprove publication of the finished
manuscript.
Measurement and Analysis
Our institutional ethics committee and an independent ethics committee
review board approved this study. We compared results from 1849 patients
before (phase 0) with 256 patients after (phase 2) universal implementa-
tion, and then the results of stopping the protocol in 222 patients (phase
3), to determine the influence of ATC on outcomes. Two hundred
fifty-eight patients were approached for consent in phase 2, and 256 agreed
to provide consent to participate. A complete set of data was available from
all patients except for chest tube drainage (n ¼ 234) and ventilator hours
(n ¼ 255) in phase 2.
Comparisons of categorical variables used a c2 or Fisher exact test, as
appropriate, whereas comparisons of continuous variables used Welch
test if the variable was symmetrically distributed and Wilcoxon rank sum
test if the variable had a skewed distribution. Propensity scoring was
used to balance the distributions of measured potentially confounding
baseline covariates using the matchit function from the R package MatchIt
(R Foundation for Statistical Computing, Vienna, Austria) with 1:1 nearest
neighbor matching based on age, gender, operative status (urgent or elec-
tive), redo status, procedure (CABG, valve, CABG þ valve, or other),
and use of anticoagulants. The analysis compared matched pairs using
McNemar test for categorical variables, paired t tests for symmetrically
distributed variables, andWilcoxon signed-rank test for skewed continuous
variables.RESULTS
The overall incidence of RBS at baseline (phase 0) was
19.5% (360 out of 1849). The incidence of RBS in phase
0 was not markedly different for surgery types: 18% (182
out of 1011) for patients undergoing CABG-only, 19%rdiovascular Surgery c Volume 151, Number 3 833
TABLE 1. Matched comparison of demographic characteristics for
phase 2 versus phase 0
Characteristic
Phase 0
(n ¼ 256)
Phase 2
(n ¼ 256)
McNemar or
paired t test
P value
Age (y) 68.6  10.6 68.1  10.9 .059
Male 197 (77) 199 (78) .68
Preoperative anticoagulation 65 (25) 62 (24) .37
Clopidogrel 37 (14) 27 (11) .22
Warfarin 15 (6) 19 (7) .56
Aspirin 173 (68) 174 (68) 1
Preoperative hematocrit
(n ¼ 255)
40.0 (4.7) 39.7 (5.5) .59
Chronic obstructive
pulmonary disease
37 (14) 42 (16) .6
Hypertension 234 (91) 241 (94) .31
New York Heart Association
functional class
I 24 (9) 17 (7) .28
II 62 (24) 38 (15) .01
III 148 (58) 179 (70) .0088
IV 21 (8) 22 (9) 1
Ejection fraction (n ¼ 255) 58.0  12.8 57.1  12.4 .44
Operative type
Coronary artery bypass
grafting
150 (59) 148 (58) .89
Valve 60 (23) 65 (25) .55
Coronary artery bypass
grafting þ valve
20 (8) 20 (8) 1
Other 26 (10) 23 (9) .37
Elective status 181 (71) 178 (70) .45
Required reoperation 21 (8) 23 (9) .48
Coronary artery bypass
time (min) (n ¼ 251)
96.3  56.3 98.1  49.0 .57
Crossclamp time (min)
(n ¼ 251)
57.5  32.2 57  31.5 .87
Deep hypothermic
circulatory arrest
6 (2) 3 (1) .45
Values are presented as mean  standard deviation or n (%).
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M(82 out of 436) for patients undergoing valve surgery, 21%
(55 out of 260) for patients undergoing combined valve/
CABG, 29% (41 out of 142), 25% (36 out of 142) for pa-
tients undergoing other types of surgery. Patients in phase
0 and phase 2 were comparable, except an increased number
of patients with CABG/valve in phase 0 and slightly higher
New York Heart Association (NYHA) class II and III
patients in phase 2 (Table E1). In phase 2 there was a
42% reduction in the primary end point of RBS from
19.5% (360 out of 1849) to 11.3% (29 out of 256)
(Table E2).
To account for potential differences between phase 0 and
phase 2, a propensity score model was used to match a
subcohort of patients in phase 0 who were well balanced
for comorbidities and operative variables with patients in
phase 2. After propensity matching, 256 of 1849 patients
in phase 0 were selected for comparison with 256 patients
in phase 2. Propensity-score matching between phase
0 and 2 found agreement for 97.7% for gender, 97.3%
for operative status, 80.9% for procedures, 98.1% for the
use of anticoagulants, 99.2% for redo status, and 95.7%
for an age difference<5 years. After matching, there were
no differences between phase 0 and phase 2 with respect
to age, sex, preoperative anticoagulation, hematocrit,
chronic obstructive pulmonary disease, hypertension,
ejection fraction, operative type, elective status, reoperative
status, cardiopulmonary bypass time, crossclamp time, or
the use of deep hypothermic circulatory arrest (Table 1).
There was a slightly higher number of NYHA class III in
phase 2 compared with matched patients in phase 0,
although NYHA class I and IVwere similar and the ejection
fractions were not statistically different between groups.
Following matching, 19.9% (51 out of 256) had at least 1
intervention for RBS in phase 0 (Table 2). Of matched
patients with RBS in phase 0, 4.7% (12 out of 256)
underwent re-exploration for bleeding, 2.7% (7 out of
256) underwent an intervention for pericardial effusion,
11.7% (30 out of 256) underwent an intervention for pleural
effusion (thoracentesis or chest tube drainage), and 3.9%
(10 out of 256) underwent an intervention for pneumo-
thorax (Table 2). After the universal implementation of
ATC in phase 2, the percent of matched patients with
interventions for ATC was reduced by 43% to 11.3% (29
out of 256) (P ¼ .0087). This was primarily due to a
reduction in interventions to treat pleural effusions. The
incidences of re-exploration for bleeding, interventions
for pericardial effusions, and interventions for pneumo-
thorax were lower in phase 2 than in matched patients in
phase 0; however, individually the differences did not reach
statistical significance. Phase 2 patients had a significantly
reduced incidence of POAF overall compared with matched
patients in phase 0 (P ¼ .013). There was not a statistically
significant reduction in hospital mortality, cardiac arrest, or
permanent stroke. Median chest drainage (P ¼ .0024) and834 The Journal of Thoracic and Cardiovascular Surgventilation hours (P ¼ .0047) were reduced in phase 2
compared with matched patients in phase 0, but not length
of stay (P ¼ .24) (Table 3).
The baseline was reassessed for potential temporal trends
after the completion of phase 2. Matched patients in phase 3
and phase 0 remained similar in terms of age, gender,
preoperative anticoagulation, chronic obstructive pulmo-
nary disease, hypertension, ejection fraction, operative
type, elective status, reoperative status, cardiopulmonary
bypass time, and crossclamp time (Table 4). There was a
slightly higher number of NYHA class III in phase 3
compared with matched patients in phase 0, although
NYHA class I and IV were not statistically different. The
mean ejection fraction was slightly lower in phase 3
(58.3%  13.1% vs 54.9%  13.8% P ¼ .01). Operativeery c March 2016
TABLE 2. Propensity-matched postoperative outcomes in phase 2
versus phase 0
Outcome
Phase 0
(n ¼ 256)
Phase 2
(n ¼ 256) % Reduction
P
value
Retained blood syndrome
(composite)
51 (19.9) 29 (11.3) 43 .0087
Re-exploration 12 (4.7) 9 (3.5) 26 .65
Pleural intervention 30 (11.7) 17 (6.6) 44 .061
Pericardial intervention 7 (2.7) 1 (0.4) 85 .077
Pneumothorax 10 (3.9) 7 (2.7) 44 .63
Postoperative atrial
fibrillation
78 (30) 52 (20) 33 .013
Stroke 4 (2) 4 (2) 0 1
Mortality 2 (5) 12 (5) 0 1
Values are presented as n (%).
Sirch et al Perioperative Management: Cardiaccharacteristics were similar, except a higher number of pa-
tients undergoing deep hypothermic circulatory arrest in
phase 0 (6 [3%] vs 0 [0%]; P ¼ .041). The RBS rate was
comparable in phase 3 (17.6%) versus matched baseline
phase 0 patients (17.6%) (P ¼ 1), as was the POAF rate
(31.5% in phase 3 vs 23.9% in matched phase 0;
P ¼ .079) (Table 5). A significant reduction in ventilator
time persisted from matched phase 0 to matched phase 3
patients (Table 6).P
MDISCUSSION
Chest tubes can obstruct, limiting their evacuation
capacity. In a survey of cardiothoracic surgeons and cardiac
surgery nurses, 100% had observed chest tube clogging and
a large majority recognized adverse events related to this
complication.2 In a prospective observational study, 36%
of chest tubes were documented as occluded after heart
surgery within the first 24 hours.3 Current methods to
prevent chest tube clogging, such as chest tube stripping
and milking, have not been shown to be effective, and
may be harmful.8,9
We set out to define the incidence of RBS at our
institution and determine if a protocol to better maintain
chest tube patency improves outcomes. We focused
specifically on interventions for retained blood rather than
more broadly on diagnosis of retained blood because the
need for an intervention suggests a more clinically relevant
subset of patients than those who simply have a diagnosis of
an effusion, for example, but are treated medically. Our
incidence of RBS interventions was 20%. Our analysisTABLE 3. Differences between phase 2 and phase 0 for matched pairs
Variable Minimum 25th percentile
Chest tube drainage (mL) (n ¼ 231) 5750 350.0
Length of stay (d) (n ¼ 256) 115 4
Ventilator time (h) (n ¼ 255) 1590 9
The Journal of Thoracic and Casuggests that the need for interventions for RBS is not pre-
dictable preoperatively by the type of procedure performed
(CABG, valve, CABG þ valve, or other), the urgency
status, or if the case was a reoperation. Accordingly, we
chose to develop a universal use protocol with the goal of
preventing RBS by proactively maintaining chest tube
patency in all patients, rather than only selected high-risk
patients.
Next we set out to determine if by implementing our
universal protocol to keep chest tubes free of blood clot
during the early hours after heart surgery we could reduce
RBS. We chose to use the PleuraFlow Active Clearance
Technology System, a device that allows nurses to
periodically clean the entire length of the chest tube by
breaking down clots with a loop on a guide wire.4 ATC
has been shown to be highly effective reducing RBS in
preclinical studies.10,11 ATC had been assessed in a
limited evaluation to be implementable in clinical
settings.12 The clinical efficacy for ATC in reducing
postoperative complications has never been tested.
Using this methodology, we found a substantial reduction
in RBS in patients treated with the ATC protocol. In
addition, we noted a significant reduction in POAF with
the implementation of a universal ATC protocol
(Figure 1). The reduction in RBS was primarily from a
reduction in pleural and pericardial effusions. We postulate
that the mechanism of reduced effusions may in part be
related the well-described cross-talk between coagulation
and inflammation that may ensue once blood is retained
in the pericardial or pleural spaces.13,14 Studies have
documented that early pleural and pericardial effusions
are primarily exudative, bloody, and inflammatory.15-18
Blood retained in the pericardial or pleural spaces, even if
in insufficient volume to cause mechanical compressive
compromise, undergoes inflammatory changes over the
subsequent days that can result in exudative fluid
production that manifests as pericardial or pleural
effusions.19,20 As blood clots, thrombin is generated,
which amplifies an acute and chronic inflammatory
responses within the pericardial and pleural spaces.21 In
response, inflammatory mediators are locally produced
that are known to activate tissue permeability factors by
mesothelial cells, such as vascular endothelial growth factor
(VEGF).22 VEGF is the primary mediator of exudative
permeability leading to effusions.22 VEGF levels have
been shown to rise and stay elevated in effusions afterMedian 75th percentile Maximum P value
50.0 137.5 2250 .0024
0 4 65 .24
2 4.50 1141 .0047
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TABLE 4. Matched comparison of demographic characteristics for
phase 3 versus phase 0
Characteristic
Phase 0
(n ¼ 222)
Phase 3
(n ¼ 222)
McNemar or
paired t test
P value
Age (y) 67.2  11.7 67.9  11.0 .41
Male 158 (71) 160 (72) .91
Preoperative anticoagulation
Clopidogrel 36 (16) 18 (8) .012
Warfarin 18 (8) 14 (6) .58
Aspirin 136 (61) 145 (65) .37
Preoperative hematocrit
(n ¼ 219)
38.2 (5.3) 39.4 (5.9) .023
Chronic obstructive
pulmonary disease
36 (16) 28 (13) .34
Hypertension 199 (90) 203 (91) .6
New York Heart Association
functional class
I 18 (8) 10 (5) .17
II 64 (29) 20 (9) <.001
III 120 (54) 173 (78) <.001
IV 20 (8) 19 (9) 1
Ejection fraction (n ¼ 219) 58.3 (13.1) 54.9  13.8 .01
Operative type
Coronary artery bypass
grafting
115 (52) 112 (50) .81
Valve 56 (25) 64 (29) .14
Coronary artery bypass
grafting þ valve
29 (13) 28 (13) 1
Other 22 (10) 18 (8) .57
Elective status 158 (71) 154 (69) .74
Required reoperation 10 (5) 12 (5) .72
Cardiopulmonary bypass
(min) (n ¼ 219)
95.3  45.1 96.8  47.3 .69
Crossclamp time (min)
(n ¼ 219)
58.2  30 57.7  29.7 .89
Deep hypothermic circulatory
arrest
6 (3) 0 (0) .041
Values are presented as mean  standard deviation or n (%).
TABLE 5. Propensity-matched postoperative outcomes phase 3 versus
phase 0
Outcome
Phase 0
(n ¼ 222)
Phase 3
(n ¼ 222)
P
value
Retained blood syndrome (composite) 39 (17.6) 39 (17.6) 1
Re-exploration 10 (4.5) 6 (2.7) .45
Pleural intervention 25 (11.3) 26 (11.7) 1
Pericardial intervention 1 (0.5) 3 (1.4) .62
Pneumothorax 5 (2.3) 8 (3.6) .58
Postoperative atrial fibrillation 70 (31.5) 53 (23.9) .079
Stroke 5 (2.3) 2 (0.9) .45
Mortality 12 (5.4) 12 (5.4) .45
Values are presented as n (%).
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to weep into the pleural and pericardial spaces, resulting in
bloody effusions. One mechanism to explain the reduction
in clinically significant effusions with ATC is that by
more completely evacuating the shed blood around the heart
and lungs, less blood is retained, and subsequently less
inflammation and VEGF is generated locally. The result
may be less inflammation of the mesothelial cells lining
the pleura and pericardium to drive exudative fluid
production that results in effusions.
This same mechanism might also contribute to the
reduction in POAF. Although there may be many factors
that contribute to the development of POAF, RBS in the
pericardium has been linked with playing a significant
role, perhaps by inducing surface cardiac irritation and836 The Journal of Thoracic and Cardiovascular Surginflammation.24,25 Studies3,26 have linked both chest tube
clogging and retained pericardial blood with POAF. Other
studies26,27 have demonstrated that shunting blood
through pericardial windows to divert the blood to the
pleural spaces reduces POAF. One advantage that ATC
may have over pericardiotomy is that the blood is not
simply shunted to the pleural spaces (where it can
contribute to pleural effusions) and there may be less
potential for complications such as herniation and long-
term adhesions of the lung to the heart through the widely
opened posterior pericardium.
There was not an appreciable reduction in the need for
re-explorations for hemorrhage with the use of ATC in
phase 2 versus phase 0. Re-explorations for bleeding are
primarily for surgical bleeding, but in some cases no
bleeding sources are noted and only clot in and around
the mediastinum is found.6 One would not expect a
reduction in re-explorations to manage surgical bleeding
sources by simply improving drainage. In theory, improved
drainage may allow a patient with a medical source of
bleeding to stay stable in the ICU longer, perhaps avoiding
tamponade and thus the trigger to return to the operating
room for re-exploration while the coagulation defect is
corrected. Similarly, the addition of a single ATC in the
mediastinum did not reduce the need for interventions for
pneumothorax in this study.
As part of this continuous quality initiative, we exam-
ined the data for temporal trends over the course of the
study. In phase 3 there was a rebound of RBS and
POAF after cessation of the ATC protocol employed in
phase 2 suggesting a return of the primary end point.
There was also a trend toward reduced ventilator time
(in hours) and length of stay over the course of this study
through the end of phase 3 suggesting other temporal
trends not accounted for by ATC. This may be attributed
to other quality improvement efforts in the ICU during
the study intervals and thus not likely associated with
the use of ATC. There also appeared to be a reduction
in the mean total blood loss in phase 2 versus 0. Individualery c March 2016
TABLE 6. Median differences between phase 3 and phase 0 for matched pairs
Variable Minimum 25th percentile Median 75th percentile Maximum P value
Chest tube drainage (mL) (n ¼ 209) 3850 270 50.0 150 2090 .084
Length of stay (d) (n ¼ 222) 62 5 1 3 53 .074
Ventilator time (h) (n ¼ 219) 1158 12 3 2 674 <.001
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significance of this finding is unclear in this study. One
can postulate that perhaps by having an open and
functioning chest tube on suction while the patient is
bleeding, there is less opportunity for blood to pool around
the heart and mediastinum and that this may lead to
less pericardial thrombolytic effect and therefore less
microvascular bleeding. Further studies to better under-
stand the influence of ATC on chest tube outputs are
indicated.
We believe this study is important for a number of
reasons. Chest tubes are used during every cardiac surgery
procedure, with a known failure rate due to clogging that
is much higher than previously expected.2,3 The finding
that nearly 20% of patients require interventions for RBS
suggests this problem is a clinically significant and
potentially a modifiable problem. The current approaches
to preventing chest tube clogging, such as milking and
stripping, have been shown to be ineffective and may be
potentially harmful.8,9 Makeshift approaches such as
opening tubes (after clogging occurs) and suctioning them
or using a balloon catheter to remove clots raise safetyFIGURE 1. Outcomes for matched p
The Journal of Thoracic and Caconcerns.28,29 Given the lack of suitable methods to
routinely prevent chest tube clogging in the ICU, this
study is a step toward studying alternatives.
Although the results are encouraging, important limita-
tions need to be considered. This was not a randomized,
prospective trial. As such, we did not control for all
variables during the study period. There may have been
changes in ICU protocols and other variables that limit
the ability to draw conclusions about ventilator times,
especially in this study. An additional limitation was that
this was a retrospective study of prospectively collected
database elements, and such databases may contain
incomplete information or errors in the manual extraction
of data. Furthermore, there were data elements that were
not collected this study, particularly with regard to the
numbers and locations of conventional chest tubes, reasons,
and findings at re-exploration for bleeding, cytology of
effusions, and details regarding coagulopathy. These are
important considerations for further study. Although the
study size was large enough to compare baseline (phase
0) to phases 2 and 3, the sizes of phase 2 and 3 were too
small for robust statistical comparison between theseatients in phase 0 versus phase 2.
rdiovascular Surgery c Volume 151, Number 3 837
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(need for interventions), but did not use direct imaging
modalities to quantify the amount of retained blood, which
will be considered for further studies. Finally, this analysis
did not include the economic data comparing the cost of the
technology versus the cost savings from complication
avoidance. This is a critical variable in the assessment of
any new modality and will be considered in subsequent
studies.
CONCLUSIONS
We observed a signification reduction in the composite
end point of RBS as well as interventions for pleural
effusions and POAF. These reductions were associated
with implementing a formal ATC protocol universally in
consecutive patients undergoing heart surgery. Our findings
underscore the importance of maintaining chest tube
patency during the early recovery period after heart surgery
and suggest the need for further studies to devise optimal
protocols to optimize chest tube patency.
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APPENDIX E1. ACTIVE TUBE CLEARANCE ACTUATION
SCHEDULE
Location Phase Timing Frequency Cycles/h
Operating
room
Chest closure 1 3 at time
of closure
4
Transfer to
intensive
care unit
1 3 at transfer
to bed
Every 15 min
Continue use
if delay
Intensive
care unit
Early bleeding 0-8 h Every 15 min 4
Slowed bleeding 8-24 h Every 30 min 2
Serosanguinous
drainage
>24 h Every 1 h 1
TABLE E1. Unmatched demographic and operative characteristics
Characteristic
Phase 0
(n ¼ 1849)
Phase 2
(n ¼ 256)
Phase 3
(n ¼ 222)
P value
(0 vs 2)
P value
(0 vs 3)
Age (y) 68.7  10.7 68.1  10.9 67.9  11.0 .4 .3
Male 1327 (72) 199 (78) 160 (72) .05 .99
Preoperative anticoagulation
Clopidogrel 382 (21) 27 (11) 18 (8) <.001 <.001
Warfarin 165 (9) 19 (7) 14 (6) .5 .24
Aspirin 1247 (67) 174 (68) 145 (65) .92 .57
Preoperative hematocrit 39.4  4.8 39.7  5.5 38.1  5.9 .3 .0038
Chronic obstructive pulmonary disease 264 (14) 42 (16) 28 (13) .42 .57
Hypertension 1680 (91) 241 (94) 203 (91) .10 .87
New York Heart Association functional class
I 139 (8) 17 (7) 10 (5) .70 .13
II 469 (25) 38 (15) 20 (9) <.001 <.001
III 1093 (59) 179 (70) 173 (78) <.001 .003
IV 145 (8) 22 (9) 19 (9) .77 .81
Ejection fraction 57.8  13.5 57.1  12.4 54.9  13.8 .44 <.001
Operative type
Coronary artery bypass grafting 1011 (54.7) 148 (57.8) 112 (50.5) .38 .26
Valve 436 (23.6) 65 (25.4) 64 (28.8) .58 .10
Coronary artery bypass grafting þ valve 260 (14.1) 20 (7.8) 28 (12.6) .0078 .63
Other 142 (7.7) 23 (9.0) 18 (8.1) .55 .93
Elective status 1246 (67) 178 (70) 154 (69) .54 .60
Required reoperation 142 (8) 23 (9) 12 (5) .55 .28
Cardiopulmonary bypass time (min) 97.2  71.1 98.1  49.0 96.8  47.3 .80 .90
Crossclamp time (min) 57.8  30.5 57.0  31.5 57.7  29.7 .69 .96
Deep hypothermic circulatory arrest 31 (2) 3 (1) 0 (0) .79 .07
Values are presented as mean  standard deviation or n (%).
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TABLE E2. Retained blood syndrome (RBS) components (unmatched)
Component
Phase 0
(n ¼ 1849)
Phase 2
(n ¼ 256)
Phase 3
(n ¼ 222)
P value
(0 vs 2)
P value
(0 vs 3)
RBS (composite) 360 (20) 29 (11) 39 (18) .0022 .56
Re-exploration 66 (3.6) 9 (3.5) 6 (2.7) 1 .70
Pleural interventions 232 (12.5) 17 (6.6) 26 (11.7) .0083 .80
Pericardial interventions 35 (1.9) 1 (0.4) 3 (1.4) .12 .79
Pneumothorax (drainage) 60 (3.2) 7 (2.7) 8 (3.6) .85 .93
Values are presented as n (%). RBS, Retained blood syndrome.
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